No. | Drug used in the study | Number of studies mentioned ADRs as drug related | Frequency (%) of patients with ADRs relevant to specific treatment regimen |
---|---|---|---|
1 | Artemether–Lumefantrine (AL) | 5 | 88/1263 (6.9%) |
2 | Artesunate–Amodiaquine (AS+AQ) | 5 | 69/1574 (4.4%) |
3 | Dihydroartemisinin–Piperaquine (DP) | 2 | 5/273 (1.8%) |
4 | Artesunate-Sulphamethoxypyrazine-Pyrimethamine (AS+SMP) | 1 | 3/250 (1.2%) |
5 | Pyronaridine:artesunate (PA) (tab & granule) | 1 | 7/30 (23.3%) |
6 | Chlorproguanil-dapsone-artesunate (CDA) | 1 | 184/914 (20.1%) |
 | Total |  | 356/4304 (8.3%) |